1. Sokolova et al., Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Gink- go biloba Extract EGb 761 and Betahistine, Int J Otolaryngol. 2014;2014:682439. doi: 10.1155/2014/682439. Epub 2014 Jun 25.


A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo bilobaextract EGb 761 and betahistine at recommended doses in patients with vertigo. One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240mg per day) or betahistine (32mg per day) for 12 weeks. An 11-point numeric analogue scale, the Vertigo Symptom Scale-short form, the Clinical Global Impression Scales and the Sheehan Disability Scale were used as outcome measures. Both treatment groups were comparable at baseline and improved in all outcome measures during the course of treatment. There was no significant intergroup difference with regard to changes in any outcome meas- ure. Numerically, improvements of patients receiving EGb 761 were slightly more pronounced on all scales. Clinical global impression was rated “very much improved” or “much improved” in 79% of patients treat- ed with EGb 761 and in 70% receiving betahistine. With 27 adverse events in 19 patients, EGb 761 showed better tolerability than betahistine with 39 adverse events in 31 patients. In conclusion, the two drugs were similarly effective in the treatment of vertigo, but EGb 761 was better tolerated. This trial is registered with ISRCTN02262139.

2. Orendorz-Fraczkowska K1, Poápiech L, Gawron W. Results of combined treatment for vestibular receptor impairment with physical therapy and Ginkgo biloba extract (Egb 761). [Article in Polish] Otolaryngol Pol. 2002;56(1):83-8.


Vestibular receptor impairment causes symptoms called vestibular organ peripheral lesion syndrome. Sub- jective and objective symptoms of vestibular lesion diminish gradually in the process of vestibular compen- sation. Stimulating a patient to action is a basic factor that influences on the compensation process. The aim of our studies was an evaluation of treatment results in patients with vertigo of peripheral origin with the use of Ginkgo biloba extract together with kinezytherapy. Ginkgo biloba extract shows vasoactive, rheologic, metabolic and neural effects. We have examined 45 persons aged between 35 and 48 years (38 on average, 35 female, 13 male) with clinical symptoms of peripheral vestibular lesion. In each case we performed as follows: ORL physical examination, pure tone audiometry, suprathreshold audiometry, electronystagmogra- phy (eyes open and closed nystagmus, cervical tests, caloric tests according to Hallpike), static and dynamic posturography. In all of the cases vestibular rehabilitation originally programmed in our Clinic was applied. N 23 cases (17 female and 6 male) chosen at random, kinezytherapy together with Ginkgo biloba in tablet was applied: 2 tablets twice a day for 3 months. Control examination were performed on 30, 60 and 90 days of treatment. Treatment results evaluation was based on anamnesis, electronystagmography, static and dy- namic posturography.


Estas páginas contienen información restringida exclusivamente a profesionales sanitarios

La información de las siguientes páginas está dirigida a los profesionales sanitarios habilitados para prescribir o dispensar medicamentos. Schwabe Farma Iberica S.A.U, no se hace responsable del uso ilegal, indebido, de la manipulación de los contenidos e informaciones de esta página. El acceso a estas páginas o el uso que pueda hacerse de la información y contenidos de la misma, será exclusivamente responsabilidad de quien lo realice.